286 related articles for article (PubMed ID: 38186874)
21. Revisiting the role of acute kidney injury in patients on immune checkpoint inhibitors: a good prognosis renal event with a significant impact on survival.
García-Carro C; Jhaveri KD; Sprangers B
Clin Kidney J; 2023 May; 16(5):773-775. PubMed ID: 37151419
[TBL] [Abstract][Full Text] [Related]
22. Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations.
Perazella MA; Sprangers B
Clin Kidney J; 2021 May; 14(5):1301-1306. PubMed ID: 33970161
[TBL] [Abstract][Full Text] [Related]
23. The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis.
Chang Y; Lin WY; Chang YC; Huang CH; Tzeng HE; Abdul-Lattif E; Wang TH; Tseng TH; Kang YN; Chi KY
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612290
[TBL] [Abstract][Full Text] [Related]
24. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
Front Oncol; 2022; 12():753234. PubMed ID: 35280736
[TBL] [Abstract][Full Text] [Related]
25. Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma.
Yin J; Elias R; Peng L; Levonyak N; Asokan A; Christie A; Kubiliun N; Brugarolas J; Hammers HJ
Clin Genitourin Cancer; 2022 Jun; 20(3):260-269. PubMed ID: 35277350
[TBL] [Abstract][Full Text] [Related]
26. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.
Seethapathy H; Zhao S; Chute DF; Zubiri L; Oppong Y; Strohbehn I; Cortazar FB; Leaf DE; Mooradian MJ; Villani AC; Sullivan RJ; Reynolds K; Sise ME
Clin J Am Soc Nephrol; 2019 Dec; 14(12):1692-1700. PubMed ID: 31672794
[TBL] [Abstract][Full Text] [Related]
27. The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Li C; Xia Z; Li A; Meng J
Ann Transl Med; 2020 Dec; 8(24):1655. PubMed ID: 33490167
[TBL] [Abstract][Full Text] [Related]
28. Cytokines and Immune Cell Phenotype in Acute Kidney Injury Associated With Immune Checkpoint Inhibitors.
Farooqui N; Zaidi M; Vaughan L; McKee TD; Ahsan E; Pavelko KD; Villasboas JC; Markovic S; Taner T; Leung N; Dong H; Alexander MP; Herrmann SM
Kidney Int Rep; 2023 Mar; 8(3):628-641. PubMed ID: 36938084
[TBL] [Abstract][Full Text] [Related]
29. Incidence, risk factors and prognosis of acute kidney injury in patients treated with immune checkpoint inhibitors: a retrospective study.
Ji MS; Wu R; Feng Z; Wang YD; Wang Y; Zhang L; Sun XF; Chen XM; He KL; Cai GY
Sci Rep; 2022 Nov; 12(1):18752. PubMed ID: 36335144
[TBL] [Abstract][Full Text] [Related]
30. Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis.
Deng R; Zhang H; Li Y; Shi Y
J Immunother; 2023 Feb-Mar 01; 46(2):43-55. PubMed ID: 36301729
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint inhibitors in patients with chronic kidney disease: Assessing their ability to cause acute kidney injury and informing their proper use.
Min JW; Lim JU
Semin Oncol; 2022 Apr; 49(2):141-147. PubMed ID: 35264308
[TBL] [Abstract][Full Text] [Related]
32. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
[TBL] [Abstract][Full Text] [Related]
33. Acute kidney injury associated with anti-PD-1 and anti-PD-L1 drugs: a meta-analysis of randomized clinical trials.
Lima IG; Silva IBUCD; Pípolo VC; Delfino VDA; Bignardi PR
Immunopharmacol Immunotoxicol; 2024 Jun; ():1-12. PubMed ID: 38825890
[TBL] [Abstract][Full Text] [Related]
34. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors.
Guven DC; Ozbek DA; Sahin TK; Kavgaci G; Aksun MS; Erul E; Yildirim HC; Chalabiyev E; Cebroyilov C; Yildirim T; Dizdar O; Aksoy S; Yalcin S; Kilickap S; Erman M; Arici M
Anticancer Drugs; 2023 Jul; 34(6):783-790. PubMed ID: 36729111
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury.
Sprangers B; Leaf DE; Porta C; Soler MJ; Perazella MA
Nat Rev Nephrol; 2022 Dec; 18(12):794-805. PubMed ID: 36168055
[TBL] [Abstract][Full Text] [Related]
36. Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis.
Dar S; Merza N; Qatani A; Rahim M; Varughese T; Mohammad A; Masood F; Reza FZ; Wan S; Almas T
Ann Med Surg (Lond); 2022 Jun; 78():103752. PubMed ID: 35600176
[TBL] [Abstract][Full Text] [Related]
37. Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy: Single Center Experience of Management and Drug Rechallenge.
Manohar S; Ghamrawi R; Chengappa M; Goksu BNB; Kottschade L; Finnes H; Dronca R; Leventakos K; Herrmann J; Herrmann SM
Kidney360; 2020 Jan; 1(1):16-24. PubMed ID: 35372854
[TBL] [Abstract][Full Text] [Related]
38. Immune Checkpoint Inhibitor-Associated Nephrotoxicity.
Mamlouk O; Danesh FR
Nephron; 2024; 148(1):11-15. PubMed ID: 37257429
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events.
Isik B; Alexander MP; Manohar S; Vaughan L; Kottschade L; Markovic S; Lieske J; Kukla A; Leung N; Herrmann SM
Kidney Int Rep; 2021 Apr; 6(4):1022-1031. PubMed ID: 33912752
[TBL] [Abstract][Full Text] [Related]
40. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.
Hart E; Dunn TE; Feuerstein S; Jacobs DM
Pharmacotherapy; 2019 Apr; 39(4):443-453. PubMed ID: 30779194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
